[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Research Letter
January 12, 2016

Global Use of Peripheral Blood vs Bone Marrow as Source of Stem Cells for Allogeneic Transplantation in Patients With Bone Marrow Failure

Author Affiliations
  • 1Department of Pediatrics and Adolescent Medicine, University of Freiburg, Freiburg, Germany
  • 2European Society for Blood and Marrow Transplantation Transplant Activity Survey Office, University Hospital, Basel, Switzerland
  • 3Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee
  • 4Australasian Bone Marrow Transplant Recipient Registry, Royal Melbourne Hospital, Parkville, Australia
  • 5Hematology-Oncology Department, University Hospital, Leipzig, Germany
  • 6Asia Pacific Blood and Marrow Transplant Group Data Centre Nagakute Campus, Aichi Medical University, School of Medicine, Nagakute, Japan
JAMA. 2016;315(2):198-200. doi:10.1001/jama.2015.13706

Hematopoietic stem cell transplantation (HSCT) is a therapeutic option for many patients with bone marrow failure.1 Bone marrow was initially the only stem cell source available until the 1990s when peripheral blood stem cells (PBSCs) and cord blood began to be used.

Currently, PBSCs are the major stem cell source,2 owing to faster engraftment and ease of collection despite a higher rate of graft-vs-host disease and lower survival rates in patients with nonmalignant disorders.3

Therefore, bone marrow is currently recommended for HSCT in patients with bone marrow failure.4 The objectives of this study were to investigate the use of PBSCs and bone marrow as stem cell sources for HSCT in patients with bone marrow failure worldwide and to identify potential factors associated with the use of each stem cell source.